hers semaglutide shortage Drug compounders sue FDA over declaration ending Wegovy Telehealth firm Hims & Hers

Progress and challenges towards targeted delivery of cancer therapeutics

Ready to start your weight loss journey with effective GLP-1 medications

doi:10.1186/1471-2369-14-98

Jodie Pepin, clinical pharmacy program director at Harbor Health and an assistant professor of pharmacy at the University of Texas in Austin, explained that millions of people have taken these medications, and the more people who take them, the more likely these associations may occur

The FDA issued guidance in 2023 stating BPC-157 cannot be compounded by 503A or 503B pharmacies in the United States because it is not on the approved bulk substances list

: GLP1